Enveric Biosciences (ENVB) EPS (Basic) (2010 - 2026)
Enveric Biosciences (ENVB) posted EPS (Basic) of -$1.08 for Q1 2026, up 91.04% sequentially from -$12.07 in Q4 2025, and up 92.58% YoY from -$0.56 in Q1 2025.
Enveric Biosciences (ENVB) EPS (Basic) (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported EPS (Basic) for 17 years, with the latest figure at -$1.08 in Q1 2026.
- Quarterly EPS (Basic) rose 92.58% year-over-year to -$1.08 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.67 (up 87.65% YoY) and the FY2025 annual result came in at -$36.24, up 84.14% from the prior year.
- EPS (Basic) grew to -$1.08 in Q1 2026 per ENVB's latest filing, from -$12.07 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$1.08 in Q1 2026 and troughed at -$1095.7 in Q4 2022.
- A 5-year average of -$271.58 and a median of -$110.52 in 2024 frame the typical range for EPS (Basic).
- The widest YoY moves for EPS (Basic): up 93.17% in 2022, down 28.03% in 2022.
- Over 5 years, EPS (Basic) stood at -$1095.7 in 2022, then soared by 73.86% to -$286.45 in 2023, then soared by 73.72% to -$75.28 in 2024, then surged by 83.97% to -$12.07 in 2025, then jumped by 91.04% to -$1.08 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$1.08, -$12.07, and -$10.81 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.18 |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | -0.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.08 |
| Dec 31, 2025 | -12.07 |
| Sep 30, 2025 | -10.81 |
| Jun 30, 2025 | -11.65 |
| Mar 31, 2025 | -14.59 |
| Dec 31, 2024 | -75.28 |
| Sep 30, 2024 | -43.10 |
| Jun 30, 2024 | -44.58 |
| Mar 31, 2024 | -110.52 |
| Dec 31, 2023 | -286.45 |
| Sep 30, 2023 | -234.68 |
| Jun 30, 2023 | -546.57 |
| Mar 31, 2023 | -415.80 |
| Dec 31, 2022 | -1,095.67 |
| Sep 30, 2022 | -262.11 |
| Jun 30, 2022 | -490.66 |
| Mar 31, 2022 | -961.33 |
| Dec 31, 2021 | -16,046.30 |
| Sep 30, 2021 | -1,055.00 |
| Jun 30, 2021 | -383.24 |